Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585221 · ClinicalTrials.gov registry record · Phase 2
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00585221 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 8 participants.
The verdict
NCT00585221, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Imatinib (IM) has dramatically improved survival of gastrointestinal stromal tumors (GIST). However, most patients become resistant to IM in less than two years. This clinical trial combines targeted therapy (IM) with immunotherapy (peginterferon α-2b). Hypothesis: Apoptosis/necrosis of imatinib-sensitive GIST releases GIST-specific antigens in vivo while Peginterferon α-2b fulfills the role of cytokine signal (danger signal), this combination can induce effective innate and adaptive anti-GIST immunity, which can eradicate imatinib-resistant clones and GIST stem cells via recognition of common antigens shared with imatinib-sensitive GIST, leading to improved response rate and remission duration.
Interventions
- DRUG Imatinib
- DRUG Peginterferon-alpha 2b (PegIFNa2b);
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585221
The ClinicalTrials.gov registry entry for NCT00585221 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib is the first listed.
NCT00585221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585221 about?
NCT00585221 is a clinical study titled "Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients". Imatinib (IM) has dramatically improved survival of gastrointestinal stromal tumors (GIST). However, most patients become resistant to IM in less than two years. This clinical trial combines targeted therapy (IM) with immunotherapy (peginterferon α-2b). Hypothesis: Apoptosis/necrosis of imatinib-sen...
What is the current status of trial NCT00585221?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2007-07. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00585221?
The interventions under investigation include: Imatinib (DRUG), Peginterferon-alpha 2b (PegIFNa2b); (DRUG).
Who is sponsoring clinical trial NCT00585221?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.